Protalix BioTherapeutics Inc. (NYSE AMERICAN: PLX)
$1.17
+0.0150 ( +1.30% ) 255.9K
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Market Data
Open
$1.17
Previous close
$1.15
Volume
255.9K
Market cap
$85.78M
Day range
$1.13 - $1.17
52 week range
$1.02 - $2.09
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Jun 28, 2024 |
ars | Annual reports | 1 | May 17, 2024 |
10-q | Quarterly Reports | 55 | May 10, 2024 |
8-k | 8K-related | 16 | May 10, 2024 |
def | Proxies and info statements | 5 | Apr 29, 2024 |
4 | Insider transactions | 1 | Apr 03, 2024 |
10-k | Annual reports | 103 | Mar 14, 2024 |
8-k | 8K-related | 17 | Mar 14, 2024 |
8-k | 8K-related | 15 | Dec 26, 2023 |
10-q | Quarterly Reports | 56 | Nov 06, 2023 |